



Forum for Collaborative HIV Research

Clinical Implications of Observational Cohort Analyses in Assessing Cardiovascular Disease Risk

June 22, 2010
Doubletree Hotel
Washington DC

Meeting Agenda

June 21, 2010		
Faculty on their own		
June 22, 2010		
<u>Session I: Goals and Objectives</u>		
Moderator: Judy Aberg, Jur Strobos		
8:00-8:30a.m.	Breakfast	
8:30-8:40 a.m.	Goals & Objectives; Introductions	Jur Strobos (Forum Co-Chair)
8:40-8:45 a.m.	Practice Implications	Judy Aberg (Executive Cmte Co-Chair)
8:45-8:50 a.m.	Impact on Guideline Development	Jeff Murray (HHS Guidelines)
8:50-9:00 a.m.	Regulatory Review	Kendall Marcus (FDA) Filip Josephson
<u>Session II: Background</u>		
What is the evidence for CVD risk in patients with HIV?		
Moderator: Heather Ribaldo, Judy Currier		
9:00-9:10 a.m.	Opening Remarks	Judith Currier
9:10-9:20 a.m.	D:A:D	Caroline Sabin
9:20-9:30 a.m.	Veterans Administration Study	Roger Bedimo
9:30-9:40 a.m.	French Hospital Database	Dominique Costagliola
9:40-10:15 a.m.	Moderated Discussion	Heather Ribaldo
10:15-10:30 a.m.	Coffee Break	

Session III: Pathophysiology
Are patients with HIV different in risk of CVD?
Moderator: Ralph D'Agostino

10:30-11:30 p.m.	<u>Moderated Discussion:</u> Demographics? Lifestyle, e.g. smoking? Hypertension, diabetes, family history? Lipodystrophy, dyslipidemia, obesity? Coagulopathy? Chronic inflammation/infection? Comorbidity, e.g. insulin resistance Concomitant medications	Panelists: Signe Worm Nisha Chandra-Strobos Morris Schambelan Judy Aberg Jeanne Triant
------------------	---	--

Session IV: Prevention, Diagnosis and Treatment
What is the clinical impact in management of CVD Risk in those patients?
Moderator: Steven Grinspoon

11:30-12:30 p.m.	<u>Moderated Discussion:</u> Calcium scores Coronary CT? Coagulation and / or inflammation Investigations, e.g. D-Dimer, IL-6, CRP Comorbidities, e.g. insulin resistance Assessment of immunological failure, viral breakthrough, viral resistance, chronic low-grade infection/bacterial translocation? Drug selection?	Panelists: Judy Aberg Roger Bedimo Jeff Taylor Chuck Cooper
------------------	--	--

12:30-1:15 p.m. Lunch

Session V: Implication for Guidelines

Objective: methods for confirmation

Moderator: Kendall Marcus, Filip Josefson

1:15-1:25 p.m.	HHS guideline process	Jeff Murray
1:25-1:35 p.m.	Impact on patient management	Judy Aberg
1:35-1:45 p.m.	Patient perspective	Bob Munk
1:45-2:00 p.m.	Discussion	

Session VI: Clinical Research Questions

Objective:

Moderator: Veronica Miller

2:00-2:45 p.m.	<u>Moderated Discussion:</u>	All
2:45-3:00 p.m.	Coffee break	

Session VII: Wrap-Up

Moderator: Jur Strobos

3:00-3:20 p.m.	Summary	
3:20-3:40 p.m.	Recommended next steps?	
3:40 p.m.	Final comments, meeting adjourn	